Breaking Down the CompX Decision

As we posted here, Judge Spencer upheld CompX International’s $39 million jury verdict against Humanscale Corporation for patent infringement. In keeping with our motto that “We read the opinions so you don’t have to,” here’s a bullet-point summary of Judge Spencer’s 40-page opinion, which can be found here and is also at 2010 U.S. Dist. LEXIS 83881 (E.D. Va. Aug. 16, 2010):

  • Non-infringement

The Court correctly held that the term “tilting” should be given its ordinary meaning and did not impermissibly allow the jury to define a disputed claim term in violation of O2 Micro Int’l. Ltd. v. Beyond Innovation Tech., Co., 521 F.3d 1351 (Fed. Cir. 2008).

  • Obviousness

Substantial evidence supported the jury’s conclusion that there was no motivation to combine previous models of CompX’s patented products to include features found in equipment supports for other types of equipment, such as sewing machines, typewriters and ironing boards.

  • On-Sale Bar

Humanscale failed to prove that sales of patented products occurred before the critical date.

  • Laches

The Court’s most in-depth analysis concerned laches. CompX had brought suit on the same patents a decade earlier, but had dismissed the suit without prejudice nine years before re-filing. The Court held that CompX’s nine-year delay was inexcusable and unreasonable but held that Humanscale failed to prove prejudice.

 In a separate ruling, found here, the Court denied CompX's claim for prejudgment interest because of the delay in filing suit, but that is a hollow victory given the size of the damage award.

If nothing else, the ruling illustrates just how difficult it is to prevail on a laches defense. Even with a nine-year delay, Humanscale could not persuade the Court that it had suffered evidentiary or economic prejudice. The case illustrates how hard it is to show evidentiary prejudice when a defendant does not know what evidence has been lost, and it’s even harder for a defendant to adamantly deny it infringes while also claiming that it suffered economic prejudice because it would have behaved differently if suit had been filed earlier.

  • Inequitable Conduct, Equitable Estoppel and Inventorship

The Court refused to reconsider its decision to grant judgment as a matter of law on these three defenses, illustrating, as was the case with laches, the heavy burden a defendant bears on these defenses.

CompX verdict upheld

In a 40 page opinion filed Monday, Chief Judge James R. Spencer of the U.S. District Court for the Eastern District of Virginia has denied several post-trial motions by the losing litigant, HumanScale, in a patent infringement case where CompX won a $19.3 million jury verdict on its counterclaims (case no. 3:09-CV-86). 

For more information on the case, see our past blog entries here (after the jury verdict) and here (after denial of a permanent injunction to CompX).

Hat tip:  Virginia Lawyers Weekly blog, which also offers a copy of the opinion for download.

NTP Goes Big Game Hunting Again

Yesterday, July 8th, Virginia patent company NTP, Inc. filed suit in the Richmond Division of the Eastern District of Virginia against pretty much every mobile technology heavyweight it had not yet sued, namely:  Apple, Google, HTC, LG, Microsoft, and Motorola.

The case numbers and complaints are listed here:

The cases allege infringement of eight patents related to e-mail and mobile devices (collectively, “the Campana Patents”).  That designation refers to Thomas Campana, who the Complaints allege invented wireless e-mail.

Five of the patents at issue were the subject of NTP’s high-stakes patent litigation war against RIM, the makers of Blackberry devices (E.D. Va. case no. 3:01-CV-767).  All of the new cases have been assigned to Chief Judge James R. Spencer, before whom NTP prevailed against RIM.  These too should draw significant media coverage.

Keep in mind that NTP also has additional suits, filed in 2006 and 2007, that are pending in the Eastern District of Virginia against Palm, T-Mobile, Verizon Wireless, AT&T, Sprint Nextel, and Alltel.  Seven of the patents involved in NTP's new suits are also at issue in its action against Palm, and all eight are at issue in the suits against the others.  Those cases are stayed pending reexamination, and as we’ve blogged before, NTP has not fared so well before the PTO (although one would not know that from the Complaints).

NTP is represented by Christian & Barton and (in at least some of the cases) by Goodwin Procter LLP and Hughes, Hubbard & Reed LLP.

 

The Jamie Foxx deception, the unquestionably accurate New York Times, and more from the "Dreamgirls" case

“Dreamgirls” fans and entertainment execs, breathe easy.  On Monday, Chief U.S. District Judge James R. Spencer granted a motion to dismiss a case brought by a pro se litigant alleging that the film infringed upon his copyright.  In Bailey v. Black Entertainment Television, Inc. et al (Eastern District of Virginia case no. 3:09-cv-00787), Plaintiff James R. Bailey sued BET, Paramount, and Viacom, asserting that the 2006 film infringed upon a screenplay he had written in 1992 named “Poison Passion.”

Bailey apparently has a copyright infringement claim history.  Defendants pointed out that he had previously claimed that the film “The Negotiator” infringed upon his work.  See Bailey v. New Regency Prods., Inc., No. 99-2525, 2000 WL 338993 (4th Cir. Mar. 31, 2000) (unpublished).  And Bailey alleged in his Complaint that the defendants had previously committed copyright infringement by using his screenplay “Topless Burning Love” to make the movie “Boomerang.”

In this Complaint about “Dreamgirls,” Bailey claimed that several of the film’s central characters (James Early, played by Eddie Murphy; Deena, played by Beyonce Knowles; and Effi, played by Jennifer Hudson) were “exact replica[s]” of characters in his work.

Defendants responded by moving to dismiss under Rule 12(b)(6) and the “Twiqbal” standard.  In their memorandum, they pointed to the 1981 Tony Award-winning Broadway play by the same name, “from which the film was adapted and which featured these very same characters with these very same names and occupations.”  They also asserted that Bailey had failed to allege the elements required when verbatim duplication is not claimed – specifically, that the defendant had access to the copyrighted work and that the defendant’s work is “substantially similar” to the protected material.

In a response titled "Motions for Constitutional and Technically Evidential Opposition to Defendants' Motions to Dismiss Case," Bailey (who “is a Historian as well as a Screenwriter” and also wrote a sci-fi novel about the Cold War) gave an interesting discourse on Hollywood depictions of Cleopatra.  He also noted that “Defendants tried to be deceptive by having actor Jamie Foxx play the characterization of 'Poison Passion's' Dominique Prince.”  And he closed on an ominous note:  “If this case is not resolved in Court ... [it] will be resolved in the Power and Law of Fate.  And whomever deserves punishment for their unlawful action(s) will in all due likelihood receive it accordingly.”

In his May 3rd Memorandum Opinion, Judge Spencer agreed that the Complaint failed to allege any access by the Defendants to Bailey’s work prior to the year 2000. 

In addition, pursuant to Fed. R. Evid. 201(b), which allows judicial notice of facts that are "capable of accurate and ready determination by resort to sources whose accuracy cannot reasonably be questioned," Judge Spencer took judicial notice of a December 21, 1981, New York Times article submitted by Defendants and regarding the Broadway production.  Because “Bailey has not presented any evidence to rebut Defendants' assertion that the characters and storyline of the 2006 film ‘Dreamgirls’ that he accuses of infringement were the same characters created for the Broadway musical ‘Dreamgirls’ in 1981, eleven years before Mr. Bailey copyrighted his screenplay,” Judge Spencer held that the Complaint failed to state a plausible claim.

Bailey has 30 days to appeal.

EDVA Judge Denies Permanent Injunction After Jury Finds Infringement

As we posted here, on February 25 a jury awarded $19 million in damages to CompX International in its patent infringement lawsuit against Humanscale Corp. Humanscale Corp. v. CompX Inter., Inc., Case No. 3:09CV86 (E.D. Va.). In a Memorandum Opinion dated April 29, Judge Spencer has denied CompX’s post-trial motion for a permanent injunction enjoining the sale of the accused products.

CompX claimed that the parties were direct competitors and that it had lost market share and customer goodwill as a result of Humanscale’s infringement.  In response, Judge Spencer held:

  • CompX’s claim of direct competition was not enough. Rather, citing the Federal Circuit’s recent decision in i4i Ltd. P’ship v. Microsoft Corp., the Court held that a patentee must point to some record evidence of direct competition. If any claim of direct competition sufficed, it “would essentially create a presumption in favor of irreparable harm, contrary to the Supreme Court’s directive in eBay.”
  • The direct competition used to justify a finding of irreparable harm typically involves a two-supplier market, which CompX had not shown.
  • Even if CompX could show some evidence of loss of market share and sales, those facts would not necessarily establish irreparable harm.
  • That the patents at issue will expire in six weeks further undermined any claim of irreparable harm.
  • The balance of hardships tipped in favor of Humanscale because of the short life left on the patents and because the injunction would prevent the sale of the accused products even though only one component of the products was found to be infringing.

CompX also moved for entry of judgment on the jury’s verdict and for an award of pre-judgment and post-judgment interest. The Court took those motions under advisement because Humanscale’s post-trial motions, particularly its laches motion, had not yet been decided. Humanscale’s motions were filed April 16 and will not be fully briefed until late May.

Baby formula case lessons regarding experts and enhanced damages

In the PBM Products v. Mead Johnson baby formula case (E.D. Va. case no. 3:09-cv-00269) followed on this blog (see prior posts here, here, and here), on Tuesday, Chief Judge James R. Spencer issued two opinions that resolve several post trial motions and offer useful pointers and reminders about expert witnesses and requests for enhanced damages and attorney's fees.

The first opinion granted PBM’s motion for judgment as a matter of law on Mead Johnson’s Lanham Act counterclaim, which challenged PBM’s comparative advertising label on its formula (“Compare to Enfamil Lipil”).  Mead Johnson contended that “PBM’s ‘compare to’ ad impliedly communicates the false message that the performance of PBM’s products has been tested and verified and is equivalent to Mead Johnson’s counterpart formulas and that the parties’ formulas are ‘identical in composition.’” 

Applying by analogy Virginia’s two-year limitations period for fraud, Judge Spencer first ruled that the statute of limitations and laches barred Mead Johnson’s claim with respect to certain PBM formulas. 

Next, Judge Spencer ruled that Mead Johnson’s evidence that the “compare to” language was impliedly false failed as a matter of law.  Mead Johnson had relied on an expert witness and consumer survey evidence.  But the survey failed to define what a key term (“the same”) meant, leading Judge Spencer to conclude that it didn’t answer “the critical question … whether consumers understand the ‘compare to’ language to make the claim that the formulas are indeed ‘identical,’ not whether the ingredients are nearly the same, substantially the same, or any other gradation one could create.”  And “[b]y failing to account for the specific allegations in this case and consider obvious alternative explanations for the results, the surveys cannot provide the required evidence needed to prove implied falsity.  And without that evidence, Mead Johnson cannot prevail on its Lanham Act claim.”

Finally, Judge Spencer held that Mead Johnson could not prove damages because its economist offered no proof of causation.  Instead, the economist “assumed that every PBM sale made was attributable to the ‘compare to’ ad on the products and that PBM would not have made any other sales but for the ad.”

In the second opinion, Judge Spencer denied both Mead Johnson’s motion for a new damages trial or for remittitur and also PBM’s motion for enhanced damages and attorney’s fees. 

In its motion, Mead Johnson found several flaws with the expert witness PBM offered on damages.  Mead Johnson also argued that the verdict was excessive when compared with similar Lanham Act claims.  Judge Spencer found that Mead Johnson “failed to carry its heavy burden of proving that the verdict in this case was against the clear weight of the evidence or based on evidence that is false” and held the size of the verdict was not a miscarriage of justice, citing other Lanham Act cases and noting that PBM did not get the full amount of damages it sought.  In particular, Judge Spencer complimented PBM’s expert on having “used a reliable regression analysis that was based on relevant and appropriate data” and “explained why certain variables were included and why others were excluded.”  Acknowledging the criticism of PBM’s expert, Judge Spencer held that criticisms of an expert witness were not enough to undermine the verdict.  “That Mead Johnson and Dr. Gering would have done it differently does not place this verdict against the weight of the evidence or show that it was based on false evidence.”

PBM’s Motion argued that enhanced damages were needed for deterrence – pointing to what it described as Mead Johnson’s recalcitrant corporate culture, untenable positions at trial, and a high public interest in truth, particularly regarding baby formula – and to fully compensate PBM.  

Judge Spencer found no reason to award enhanced damages, concluding that PBM was not undercompensated and did not show intent to distribute false advertising.  Awarding enhanced damages, according to the Court, would tip the scale from compensation to an impermissible penalty.

Finally, Judge Spencer declined to award attorney’s fees.  The Court noted that the Fourth Circuit applies a somewhat higher standard than other circuits for the award of attorney’s fees – requiring proof of “bad faith” for a prevailing plaintiff (citing Scotch Whisky Ass’n v. Majestic Distilling Co., 958 F.2d 594, 599 (4th Cir. 1991), cert. denied, 506 U.S. 862 (1992)) and “something less than bad faith” for a prevailing defendant.  The Court concluded that PBM had not shown bad faith by clear and convincing evidence and that Mead Johnson had acted aggressively, but not egregiously.

 

EDVA Jury Awards More Than $19 Million in Patent Infringement Case

On February 25, a jury found in favor of the patentee, CompX International, in the case of Humanscale Corp. v. CompX International, et al., Case No. 3:09cv86 (E.D. Va.), and awarded $19 million dollars in past damages and a reasonable royalty of 6% of future sales of infringing products. The jury’s verdict can be found here.

The patents-at-issue, U.S. Patent Nos. 5,037,054 and 5,257,767, cover adjustable platforms for computer keyboards. After an eight-day jury trial before Chief Judge Spencer in the Richmond Division of the EDVA, the jury found that Humanscale’s accused keyboards infringed three claims of the ‘054 patent and two claims of the ‘767 patent. The jury also found that the patents were valid and rejected Humanscale’s on-sale bar and laches defenses.
 

Yes, Virginia, there is a cause of action for false advertising

            In the PBM Products v. Mead Johnson baby formula case (E.D. Va. case no. 3:09-cv-00269) twice previously mentioned on this blog (here and here), Chief Judge James R. Spencer delivered a gift to counsel on Christmas Eve, in the form of the second of two Christmas week opinions that provide a full discussion of and rationale for prior rulings. 

 

            This blog entry addresses a portion of that December 24th opinion [docket no. 243 on PACER/ECF, copy available here, also available at 2009 U.S. Dist. LEXIS 120200], which dealt with Mead Johnson’s summary judgment motion on PBM’s false advertising claims under the Lanham Act and for commercial disparagement under Virginia law.  The motion was denied on the former and granted on the latter.  A passage (on p.10) about the Virginia law claim may be somewhat startling at first:

 

            “As this Court has previously held, ‘the only claims for unfair competition recognized in Virginia are palming off and misappropriation of another's work.’  PBM Products. Inc. v. Mead Johnson & Co., 204 F.R.D. 71, 75 (E.D. Va. 2001).  Thus, Virginia does not recognize a cause of action for deceptive trade practices, such as false advertising.  See id.

 

            So, does this passage really mean that those who want to sue for “deceptive trade practices, such as false advertising,” are out of luck under Virginia law?  No, as explained below.

            Following the link to the 2001 opinion, also by Judge Spencer, quickly begins to clear up the confusion.  Citing an unpublished 1994 Eastern District of Virginia opinion by Judge Cacheris (1994 U.S. Dist. LEXIS 20303) and a 1993 Fairfax County Circuit Court opinion by Judge Michael P. McWeeny (32 Va. Cir. 75), the 2001 opinion reaches the conclusions quoted above.  It makes clear, however, that what is at issue is “Virginia's narrow definition of common law unfair competition.”  204 F.R.D. at 74 (emphasis added).

 

            Further exploration of the authorities up the chain (a 1989 E.D. Va. opinion by Judge Ellis and a 1921 Supreme Court of Virginia case) confirm that what has happened – on both the federal and state level – is that legislatures have set forth what is prohibited, thereby displacing the common law’s efforts to address deceptive trade practices and false advertising through the rubric of unfair competition.  See Monoflo Int’l, Inc. v. Sahm, 726 F. Supp. 121, 127 (E.D. Va. 1989) (“there is no federal common law of unfair competition applicable here separate or apart from the Lanham Act and the judicial decisions construing that Act”); Benj. T. Crump Co. v. J. L. Lindsay, Inc., 130 Va. 144, 164, 107 S.E. 679, 685 (1921) (“we have a statute … which expressly authorizes the adoption of a form of advertisement … provides for the registration thereof, and makes it a misdemeanor for any other to counterfeit or imitate such form of advertisement, or to circulate any such imitation thereof.  The inference from the enactment of such a statute clearly is, that one who desires a monopoly of the precise form of his advertisements should take advantage of its provisions”).

 

            Indeed, Virginia has more than one statute that addresses false advertising (leaving aside industry-specific statutes).

 

            The Virginia Consumer Protection Act contains numerous advertising and trade practices provisions, including a prohibition on any “deception, fraud, false pretense, false promise, or misrepresentation in connection with a consumer transaction.”  Va. Code § 59.1-200. 

 

            Virginia’s criminal code (§ 18.2-216) makes it a Class 1 misdemeanor to, with commercial intent, “publish[], disseminate[], circulate[] or place[] before the public … an advertisement of any sort regarding merchandise, securities, service, land, lot or anything so offered to the public … contain[ing] any promise, assertion, representation or statement of fact which is untrue, deceptive or misleading, or us[ing] any other method, device or practice which is fraudulent, deceptive or misleading to induce the public to enter into any obligation.” 

 

            The General Assembly has explicitly created a private cause of action for “[a]ny person who suffers loss as the result of a violation of” that misdemeanor false advertising statute.  See Va. Code § 59.1-68.3 (allowing an action for damages or $100, whichever is greater, plus reasonable attorney’s fees for violation of Article 8 (§ 18.2-214 et seq.), Chapter 6 of Title 18.2).

 

            And last but not least, there’s the Virginia Trademark and Service Mark Act.  See Va. Code § 59.1-92.12.

 

            In sum, Virginia law offers more than one potential cause of action for deceptive trade practices, such as false advertising, but Judge Spencer’s PBM Products opinion is a good reminder that litigants need to be cognizant of the fact that this is an area of state law that is predominantly a matter of statutes, not common law.

December 2009 Baby Formula Company Awarded Injunction in False Advertising Trial

After an eight-day jury trial and a $13.5 million damages award last month in its favor, Chief Judge James R. Spencer this week granted PBM Products’ request for injunctive relief in PBM Products, LLC v. Mead Johnson Nutrition Company, et al., no. 3:09-cv-269 (E.D. Va., Richmond Div.). PBM, the maker of store-brand baby formula, had sued Mead Johnson for, among other things, false advertising. At the center of the dispute were Mead Johnson’s advertisements that its more expensive baby formula is clinically proven to improve brain and eye development, among other representations about the unique nutritional advantages of its formula in comparison to store brand formula. At trial, however, PBM was able to prove that its store-brand formula has the same nutritional values as Mead Johnson’s formula.

After the resolution of Mead Johnson’s laches defense and in light if the jury’s verdict in PBM’s favor, Judge Spencer granted PBM’s request for injunctive relief and enjoined Mead Johnson from publishing and circulating any advertisement or promotional material with any false representation about its formula and from making any false statement or representation about its formula, including “It may be tempting to try a less expensive store brand, but only Enfamil LIPIL is clinically proven to improve brain and eye development,” and “There are plenty of other ways to save on baby expenses without cutting back on nutrition.” Finally, the Court directed Mead Johnson to retrieve all advertisements, materials or literature with such claims already in the public forum.

While this may not be the last we hear of this case, the verdict is a warning to companies to be careful about comparative advertising claims that might leave a false impression even if they are not literally false.
 

Verdict in baby formula false advertising case

Your baby is priceless. Her formula’s advertising just cost $13.5 million in damages.

Yesterday, after a multi-day trial before Chief Judge James R. Spencer, the jury returned a verdict in favor of plaintiffs in PBM Products, LLC v. Mead Johnson Nutrition Company, et al., no. 3:09-cv-269 (E.D. Va., Richmond Div.).

The defendant, Mead Johnson, is the maker of one of the two Goliaths of baby formula brands – Enfamil. PBM makes store-brand formulas. This case was the third legal tangle between PBM and Mead Johnson over claims made in advertising for Enfamil, in an effort to entice parents to choose it over store brands.

In this case, PBM took aim at ad claims that “Only Enfamil has LIPIL®, our blend of DHA and ARA, important nutrients found in breast milk” and that it was an “En-Fact” that “Enfamil LIPIL’s unique formulation is not available in any store brand.” (DHA and ARA are lipids, types of fatty acids highly-touted for brain development and other nutritional value. LIPIL is Mead Johnson’s registered trademark for its blend of those lipids.)

As Judge Spencer explained in his May 7, 2009 Memorandum Opinion denying a TRO and preliminary injunction, Mead Johnson’s mailer goes on to say, “It may be tempting to try a less expensive store brand, but only Enfamil LIPIL is clinically proven to improve brain and eye development.” In noticeably smaller type, the footnote to that statement reads: “vs prior formulation of the same product without DHA and ARA, measured at 12 months for eye and 18 months for brain.” The mailer also has a graphic labeled “Visual acuity at 12 months.” The graphic is divided down the middle and contains a picture of a duck. One side of the picture looks blurry, while the other appears clear. Next to the blurry side are the words “without LIPIL®,” while the caption next to the clear side reads “with LIPIL®”.

The parties agreed that PBM’s formulas use the same level of the lipids and get them from the same supplier as Mead Johnson.

PBM sued for violations of the Lanham Act (15 U.S.C. 1125(a)(1)(A) & (B)) and commercial disparagement. Mead Johnson counterclaimed for breach of the settlement agreement in a prior lawsuit; defamation, trade libel, and product disparagement; violations of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B), in PBM’s advertisements for its store brand formulas (which invite comparison to Enfamil); and civil contempt for violation of the sealing order in the prior lawsuit.

In his May opinion, Judge Spencer found that the statements at issue were not literally false. Certain counts on both sides later were dismissed, and the case went to trial, leading to the $13.5 million verdict for PBM. Mead Johnson can take some solace, however, in the fact that PBM had been seeking $60 million.

Stay tuned as the big business and litigation over feeding the littlest people continues.